Mark Kipnes

7.2k total citations · 3 hit papers
57 papers, 4.3k citations indexed

About

Mark Kipnes is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Mark Kipnes has authored 57 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Endocrinology, Diabetes and Metabolism, 21 papers in Surgery and 10 papers in Molecular Biology. Recurrent topics in Mark Kipnes's work include Diabetes Treatment and Management (25 papers), Diabetes Management and Research (21 papers) and Pancreatic function and diabetes (15 papers). Mark Kipnes is often cited by papers focused on Diabetes Treatment and Management (25 papers), Diabetes Management and Research (21 papers) and Pancreatic function and diabetes (15 papers). Mark Kipnes collaborates with scholars based in United States, United Kingdom and Canada. Mark Kipnes's co-authors include Carolyn Mickel, Jared Lunceford, Debora Williams‐Herman, Pablo Aschner, Peter Stein, Hootan Khatami, Debra Fanurik, Kjeld Hermansen, Sunder Mudaliar and Paul Dillon and has published in prestigious journals such as Gastroenterology, Hepatology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Mark Kipnes

55 papers receiving 4.0k citations

Hit Papers

Efficacy and Safety of the Farnesoid X Receptor Agonist ... 2006 2026 2012 2019 2013 2006 2022 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
    2013 767 citations Sunder Mudaliar, Robert R. Henry et al. Gastroenterology profile →
  2. Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 Diabetes
    2006 721 citations Mark Kipnes et al. profile →
  3. Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes
    2022 100 citations Satish K. Garg, Mark Kipnes et al. Diabetes Technology & Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Kipnes United States 31 2.9k 1.3k 1.2k 717 713 57 4.3k
Per‐Anders Jansson Sweden 34 1.7k 0.6× 911 0.7× 1.3k 1.1× 591 0.8× 1.3k 1.9× 71 5.0k
Sven Fischer Germany 30 905 0.3× 1.1k 0.8× 775 0.6× 502 0.7× 474 0.7× 87 4.3k
Meng H. Tan United States 36 3.2k 1.1× 1.2k 0.9× 1.9k 1.5× 180 0.3× 897 1.3× 113 5.2k
Takahisa Hirose Japan 34 2.1k 0.7× 1.2k 0.9× 1.3k 1.1× 273 0.4× 1.1k 1.6× 166 4.8k
Kohei Kaku Japan 47 4.7k 1.6× 2.7k 2.0× 3.4k 2.8× 498 0.7× 796 1.1× 398 7.7k
Francesco Purrello Italy 38 2.5k 0.9× 2.2k 1.6× 1.6k 1.3× 198 0.3× 1.1k 1.6× 186 5.4k
Baptist Gallwitz Germany 39 4.2k 1.5× 2.2k 1.6× 1.9k 1.6× 672 0.9× 417 0.6× 129 5.7k
Ferdinando Carlo Sasso Italy 56 2.4k 0.8× 1.1k 0.8× 1.9k 1.6× 448 0.6× 1.6k 2.3× 178 6.7k
Theodosios D. Filippatos Greece 41 2.3k 0.8× 1.9k 1.4× 998 0.8× 194 0.3× 778 1.1× 142 4.8k
Klaus A. Dugi Germany 39 2.9k 1.0× 1.6k 1.2× 1.4k 1.2× 806 1.1× 698 1.0× 72 4.4k

Countries citing papers authored by Mark Kipnes

Since Specialization
Citations

This map shows the geographic impact of Mark Kipnes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Kipnes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Kipnes more than expected).

Fields of papers citing papers by Mark Kipnes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Kipnes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Kipnes. The network helps show where Mark Kipnes may publish in the future.

Co-authorship network of co-authors of Mark Kipnes

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Kipnes. A scholar is included among the top collaborators of Mark Kipnes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Kipnes. Mark Kipnes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Garg, Satish K., Mark Kipnes, Kristin Castorino, et al.. (2022). Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes. Diabetes Technology & Therapeutics. 24(6). 373–380. 100 indexed citations breakdown →
2.
Phillips, Edward H, Jaime Ponce, Sunil Bhoyrul, et al.. (2021). Safety and effectiveness of REALIZE adjustable gastric band: 5-year prospective study. Surgery for Obesity and Related Diseases. 17(5). 956–962. 1 indexed citations
3.
Mudaliar, Sunder, Robert R. Henry, Arun J. Sanyal, et al.. (2013). Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Gastroenterology. 145(3). 574–582.e1. 767 indexed citations breakdown →
4.
Leifke, Eckhard, Himanshu Naik, Jingtao Wu, et al.. (2012). A Multiple-Ascending-Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK-875, in Subjects With Type 2 Diabetes. Clinical Pharmacology & Therapeutics. 92(1). 29–39. 75 indexed citations
5.
Subbarayan, Sreevidya & Mark Kipnes. (2011). Sitagliptin: a review. Expert Opinion on Pharmacotherapy. 12(10). 1613–1622. 34 indexed citations
6.
Kipnes, Mark. (2011). Sodium–glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials. Clinical Investigation. 1(1). 145–156. 14 indexed citations
7.
Chacra, Antônio Roberto, Mark Kipnes, Liza L. Ilag, et al.. (2010). Comparison of insulin lispro protamine suspension and insulin detemir in basal‐bolus therapy in patients with Type 1 diabetes. Diabetic Medicine. 27(5). 563–569. 8 indexed citations
8.
Kipnes, Mark, Eli M. Roth, Carolyn M. Setze, et al.. (2009). Year Two Assessment of Fenofibric Acid and Moderate-Dose Statin Combination. Clinical Drug Investigation. 30(1). 51–61. 18 indexed citations
9.
Mudaliar, Sunder, Linda Morrow, Paul Dillon, et al.. (2009). A NEW THERAPY FOR NONALCOHOLIC FATTY LIVER DISEASE AND DIABETES? INT-747-THE FIRST FXR HEPATIC THERAPEUTIC STUDY. Hepatology. 50(4). 18 indexed citations
10.
Kipnes, Mark, Priscilla Hollander, Ken Fujioka, et al.. (2009). A one‐year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes. Diabetes Obesity and Metabolism. 12(6). 517–531. 43 indexed citations
11.
Pratley, Richard E., et al.. (2008). Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obesity and Metabolism. 11(2). 167–176. 143 indexed citations
12.
13.
Kipnes, Mark. (2007). Sitagliptin. Drugs. 67(4). 598–599. 1 indexed citations
14.
Herman, Gary, et al.. (2006). Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Current Medical Research and Opinion. 22(10). 1939–1947. 77 indexed citations
15.
16.
Wang, Christina, Ronald S. Swerdloff, Mark Kipnes, et al.. (2004). New Testosterone Buccal System (Striant) Delivers Physiological Testosterone Levels: Pharmacokinetics Study in Hypogonadal Men. The Journal of Clinical Endocrinology & Metabolism. 89(8). 3821–3829. 70 indexed citations
17.
Wolf, Bryan W., Mark Kipnes, Keith Wheeler, et al.. (2002). Glycemic and insulinemic responses of nondiabetic healthy adult subjects to an experimental acid-induced viscosity complex incorporated into a glucose beverage. Nutrition. 18(7-8). 621–626. 44 indexed citations
18.
19.
Schwartz, Sherwyn, Jerome S. Fischer, & Mark Kipnes. (2001). Sugar-Free Zinc Gluconate Glycine Lozenges (Cold-Eeze) Do Not Adversely Affect Glucose Control in Patients With Type 1 or Type 2 Diabetes Mellitus. American Journal of Therapeutics. 8(4). 247–252. 6 indexed citations
20.
Silvers, David, Mark Kipnes, Vasti L. Broadstone, et al.. (1998). Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. Clinical Therapeutics. 20(3). 438–453. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Per‐Anders Jansson Breakdown of academic impact, for papers by Sven Fischer Breakdown of academic impact, for papers by Meng H. Tan Breakdown of academic impact, for papers by Takahisa Hirose Breakdown of academic impact, for papers by Kohei Kaku Breakdown of academic impact, for papers by Francesco Purrello Breakdown of academic impact, for papers by Baptist Gallwitz Breakdown of academic impact, for papers by Ferdinando Carlo Sasso Breakdown of academic impact, for papers by Theodosios D. Filippatos Breakdown of academic impact, for papers by Klaus A. Dugi
Rankless by CCL
2026